SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused on developing targeted therapies for patients with severe rare diseases and ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Following the FDA nod in late 2023, Ogsiveo (nirogacestat) became the first approved product in the company’s portfolio and the first approved drug for treating desmoid tumors, a rare, aggressive ...

SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully ...

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for rare diseases and cancer. The company was founded in 2017 and is headquartered in Stamford, ...

The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by Guggenheim on May 12, 2025. The analyst firm set a price target for $47.00 expecting SWTX to rise to within 12 months ...

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European ...

The stock climbed after investors saw encouraging signs from a similar program. GlaxoSmithKline is developing belantamab mafodotin, a protein that delivers single-serving chemotherapy packages ...